Etiology of cancer in humans and animals

Experimental and Toxicologic Pathology

Volumn 48, Issue 2-3, 1996, Pages 95-100

  Wild, Christopher P ^a   Kleihues, Paul ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

Cancer, etiology; Carcinogenesis; Genetic susceptibility; Molecular epidemiology

Indexed keywords

CANCER; CANCER GENETICS; CHEMICAL CARCINOGENESIS; CONFERENCE PAPER; HUMAN; MOUSE; RAT; SMOKING;

ANIMALIA; HEPATITIS B VIRUS; NICOTIANA TABACUM;

EID: 0029872668     PISSN: 09402993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0940-2993(96)80029-7     Document Type: Conference Paper

References (43)

1. AGUILAR F, HARRIS CC, SUN T, et al.: Geographic variation of p53 mutational profile in nonmalignant human liver. Science 1994; 264: 1317-1319.
2. BOYD J: BRCA1: More than a heriditary cancer gene? Nature Genetics 1995; 9: 335-336.
3. BRENNAN JA, BOYLE JO, KOCH WM, et al.: Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. NEJM 1995; 332: 712-717.
4. CHEMIN I, BELLOC C, LANG M, et al.: Induction of cytochrome P450s responsible for aflatoxin metabolism in hepatitis B virus (HBV) transgenic mice. Proc Am Assoc Cancer Res 1995; 36: 146.
5. DUFLOT A, HOLLSTEIN MC, MEHROTRA R, et al.: Absence of p53 mutation at codon 249 in duck hepatocellular carcinomas from the high incidence area of Qidong (China). Carcinogenesis 1994; 7: 1353-1357.
6. 32P-postlabeling. Chem Res Tox 1994; 7: 733-739.
7. FUJIMOTO Y, HAMPTON LL, LUO L-D, et al.: Low frequency of p53 gene mutation in tumors induced by aflatoxin B1 in nonhuman primates. Cancer Res 1992; 52: 1044-1046.
8. GREENBLATT MS, BENNETT WP, HOLLSTEIN M, et al.: Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54: 4855-4878.
9. GROOPMAN JD, SABBIONI G, WILD CP: Molecular dosimetry of aflatoxin exposures. In: GROOPMAN JD and SKIPPER P (eds.): Molecular dosimetry of human cancer: epidemiological, analytical and social considerations. CRC Press, Boca Raton, Florida USA 1991 pp. 302-324.
10. GROOPMAN JD, WILD CP, HASLER J, et al.: Molecular epidemiology of aflatoxin exposures: validation of aflatoxin-N7-guanine levels in urine as a biomarker in experimental rat models and humans. Environ Health Perspect 1993; 99: 107-113.
11. HARVEY M, MCARTHUR MJ, MONTGOMERY CA, et al.: Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nature Genetics 1993; 5: 225-229.
12. HAYASHI S, WATANABE J, KAWAJIRI K: High susceptibility to lung cancer analyzed in terms of combined genotypes of P450IA1 and Mu-class glutathione S-transferasegenes. Jpn J Cancer Res 1992; 83: 866-870.
13. HOLLSTEIN M, RICE K, GREENBLATT MS, et al.: Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 1994; 22: 3551-3555.
14. HULA JE, CHEN ZY, EATON DL: Aflatoxin B1-induced rat hepatic hyperplastic nodules do not exhibit a site-specific mutation within the p53 gene. Cancer Res 1993; 53: 9-11.
15. HULKA B, WILCOSKY TC, GRIFFITH JD: Biological markers in epidemiolosy. Oxford University Press, New York USA 1990.
16. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans vol. 56. Some Naturally Occuring Substances: Food Items and Constituents, Heterocyclic Aromatic Amines and Mycotoxins, IARC Lyon, France 1993.
17. JERRY DJ, BUTEL JS, DONEHOWER LA, et al.: Infrequent p53 mutations in dimethylbenz[a]anthracene-induced mammary tumors in BALB/c and p53 hemizygous mice. Mol Carcinogenesis 1994; 9: 175-183.
18. KEMP CJ, DONEHOWER LA, BRADLEY A, et al.: Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumours. Cell 1993; 74: 813-822.
19. KEMP CJ, WHELDON T, BALMAIN A: p53 deficient mice are extremely susceptible to radiation-induced carcinogenesis. Nature Genetics 1994; 8: 66-69.
20. KEMP CJ: Hepatocarcinogenesis in p53-deficient mice. Mol Carcinogenesis 1995; 12: 132-136.
21. KINZLER KW, VOGELSTEIN B: Cancer. A gene for neurofibromatosis 2 [news; comment], Nature 1993; 363: 495-496.
22. KIRBY GM, CHEMIN I, MONTESANO R, et al.: Induction of specific cytochrome P450s involved in aflatoxin B1 metabolism in hepatitis B virus transgenic mice. Mol Carcinog 1994; 11: 74-80.
23. MARCHETTI M, ARICO B, BURRONI D, et al.: Development of a mouse model of Helicobacter pylori infection that mimics human disease. Science 1995; 267: 1655-1658.
24. MONTESANO R, WILD CP: Chemical-viral interactions in carcinogenesis. In: IVERSEN OH (Ed.): New frontiers in cancer causation: Proceedings of the second international conference on theories of Carcinogenesis. Taylor & Francis, Washington 1993 pp. 283-299.
25. OZTURK M: p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet 1991; 338: 1356-1359.
26. PARKIN DM, PISANI P, FERLAY J: Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 1993; 54: 594-606.
27. PELKONEN O, RAUNIO H: Individual expression of carcinogen-metabolising enzymes: cytochrome P450 2A. J Occup Environ Med 1995; 37: 19-24.
28. PINEAU T, FERNANDEZ-SALGUERO P, LEE SST, et al.: Neonatal lethality associated with respiratory distress in mice lacking cytochrome P450 1A2. Proc Natl Acad Sci USA 1995; 92: 5134-5138.
29. PISANI P, PARKIN DM, FERLAY J: Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int J Cancer 1993; 55: 891-903.
30. PUISIEUX A, LIM S, GROOPMAN J, et al.: Selective targeting of p53 gene mutational hotspots in human cancers by etiologically defined carcinogens. Cancer Res 1991; 51: 6185-6189.
31. QIAN GS, ROSS RK, YU MC, et al.: A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epi Bio Prev 1994; 3: 3-10.
32. RANNUG A, ALEXANDRIE A-K, PERSSON I, et al.: Genetic polymorphism of cytochromes P450 1A1, 2D6 and 2E1: regulation and toxicolosical significance. J Occup Environ Med 1995; 37: 25-36.
33. RIVKINA MB, CULLEN JM, ROBINSON WS, et al.: State of the p53 gene in hepatocellular carcinomas of ground squirrels and woodchucks with past and ongoing infection with hepadnaviruses. Cancer Res 1994; 54: 5430-5437.
34. ROSS RK, YUAN JM, YU MC, et al.: Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet 1992; 339: 943-946.
35. RUMSBY PC, DAVIES MJ, EVANS JG: Screening for p53 mutations in C3H/He mouse liver tumours derived spontaneously or induced with diethylnitrosamine or phenobarbitone. Mol Carcinogenesis 1994; 9: 71-75.
36. SELL S, HUNT JM, DUNSFORD HA, et al.: Synergy between hepatitis B virus expression and chemical hepatocarcinogens in transgenic mice. Cancer Res 1992; 51: 1278-1285.
37. SEIDEGARD J, VORACHEK WR, PERO RW, et al.: Hereditary differences in the expression of the human glutathione transferase active on transstilbene oxide are due to a gene deletion. Proc Natl Acad Sci USA 1988; 85: 7293-7297.
38. SIMULA TP, GLANCEY MJ, WOLF CR:Human glutathione S-transferase-expressing Salmonella typhimurium tester strains to study the activation/detoxification of mutagenic compounds: studies with halogenated compounds, aromatic amines and aflatoxin B1. Carcinogenesis 1993; 14: 1371-1376.
39. THAMAVIT W, NGAMYING M, BOONPUCKNAVIG V, et al.: Enhancement of DEN-induced hepatocellular nodule development by Opisthorchis viverrini infection in Syrian golden hamsters. Carcinogenesis 1987; 8: 1351-1353.
40. VINEIS P, BARTSCH H, CAPORASO N, et al.: Genetically based N-acetyltransferase metabolic polymorphism and low-level environmental exposure to carcinogens. Nature 1994; 369: 154-156.
41. WILD CP, JANSEN LA, COVA L, et al.: Molecular dosimetry of aflatoxin exposure: contribution to understanding the multifactorial etiopathogenesis of primary hepatocellular carcinoma with particular reference to hepatitis B virus. Environ Health Perspect 1993; 99: 115-122.
42. YU MC, SKIPPER PL, TAGHIZADEH K, et al.: Acetylator phenotype, aminobiphenyl-hemoglobin adduct levels, and bladder cancer risk in white, black, and Asian men in Los Angeles, California. J Natl Cancer Inst 1994; 86: 712-716.
43. ZUR HAUSEN H: Viruses in human cancers. Science 1991; 254: 1167-1173.